Beloin Christophe, Renard Stéphane, Ghigo Jean-Marc, Lebeaux David
Institut Pasteur, Unité de Génétique des Biofilms, Département de Microbiologie, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France.
Sanofi R&D, 195 route d'Espagne, 31036 Toulouse, France.
Curr Opin Pharmacol. 2014 Oct;18:61-8. doi: 10.1016/j.coph.2014.09.005. Epub 2014 Sep 23.
Biofilms formed by pathogenic bacteria and fungi are associated with a wide range of diseases, from device-related infections (such as catheters or prosthetic joints) to chronic infections occurring on native tissues (such as lung infections in cystic fibrosis patients). Biofilms are therefore responsible for an important medical and economic burden. Currently used antibiotics have mostly been developed to target exponentially growing microorganisms and are poorly effective against biofilms. In particular, even high concentrations of bactericidal antibiotics are inactive against a subset of persistent biofilm bacteria, which can cause infection recurrence despite prolonged treatments. While the search for a magic bullet antibiotic effective against both planktonic and biofilm bacteria is still active, alternative preventive and curative approaches are currently being developed either limiting adhesion or biofilm formation or targeting biofilm tolerance by killing persister bacteria. Most of these approaches are adjunctive using new molecules in combination with antibiotics. This review presents promising approaches or strategies that could improve our ability to prevent or eradicate bacterial biofilms in medical settings.
由致病细菌和真菌形成的生物膜与多种疾病相关,从与器械相关的感染(如导管或人工关节感染)到发生在天然组织上的慢性感染(如囊性纤维化患者的肺部感染)。因此,生物膜造成了重大的医学和经济负担。目前使用的抗生素大多是针对指数生长的微生物开发的,对生物膜的效果不佳。特别是,即使是高浓度的杀菌抗生素对一部分持续存在的生物膜细菌也没有活性,这些细菌即使经过长时间治疗仍可导致感染复发。虽然寻找一种对浮游细菌和生物膜细菌都有效的神奇抗生素的研究仍在进行,但目前正在开发替代的预防和治疗方法,要么限制粘附或生物膜形成,要么通过杀死持留菌来靶向生物膜耐受性。这些方法大多是辅助性的,将新分子与抗生素联合使用。本综述介绍了一些有前景的方法或策略,这些方法或策略可以提高我们在医疗环境中预防或根除细菌生物膜的能力。